Glucose Laboratoire Aguettant

Glucose Laboratoire Aguettant is an intravenous glucose solution supplied as a prescription‑only product in the European market. The preparation contains glucose as the sole active ingredient and is provided in a sterile liquid form for parenteral administration. It is manufactured by Laboratoire Aguettant and is intended for use under medical supervision to support patients who require intravenous carbohydrate supplementation in settings such as surgery or critical care.

Glucose Laboratoire Aguettant is used as an intravenous source of carbohydrate to provide energy and maintain blood glucose levels in various clinical situations.

- Management of hypoglycemia when oral intake is not possible. - Provision of caloric support during peri‑operative fasting. - Maintenance of plasma glucose in patients receiving total parenteral nutrition. - Support for patients in intensive care units who have increased metabolic demands. - Replacement of fluid and electrolytes when combined with appropriate additives.

Adverse reactions to intravenous glucose solutions are generally infrequent, but they can be categorized by frequency and severity.

Common: - Mild hyperglycemia (transient elevation of blood glucose). - Local irritation at the infusion site. - Nausea or vomiting. - Headache.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Allergic or anaphylactic reaction to the solution components. - Electrolyte imbalance (e.g., hyponatremia) when administered in large volumes. - Thrombophlebitis at the catheter site.

When using Glucose Laboratoire Aguettant, clinicians should observe several precautions to ensure patient safety and therapeutic effectiveness.

- Verify patient’s blood glucose level before and during infusion. - Adjust infusion rate according to individual metabolic needs and clinical condition. - Use aseptic technique to prevent contamination of the sterile solution. - Monitor for signs of fluid overload, especially in patients with cardiac or renal impairment. - Consider electrolyte status, as large volumes may affect sodium and potassium balance. - Avoid use in patients with known hypersensitivity to glucose solutions.

Intravenous glucose can interact with other medications or clinical conditions, influencing both efficacy and safety.

Avoid: - Co‑administration with insulin bolus doses without appropriate glucose monitoring. - Simultaneous infusion of high‑concentration dextrose with calcium‑containing solutions, which may cause precipitation.

Use with caution: - Concurrent use of diuretics that may alter fluid and electrolyte balance. - Administration alongside medications that affect blood glucose, such as glucocorticoids or beta‑agonists. - Patients receiving parenteral nutrition containing other carbohydrate sources to prevent excess caloric intake.